micro-community-banner
 
  • Saved

3yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.

  • Saved

3yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.


  • Saved

3yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.


  • Saved

3yr
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study - Neurological Sciences

Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study - Neurological Sciences

Source : https://link.springer.com/article/10.1007/s10072-022-06190-w

Previous studies reported a positive effect of anti-CGRP monoclonal antibodies (mAbs) in migraine prevention, either in over (O65) and under (U65) 65-year-aged patients. The aim of our study was to...


Relevance: Previous studies reported a positive effect of anti-CGRP monoclonal antibodies (mAbs) in migraine prevention, either in over (O65) and under (U65) 65-year-aged patients. The aim of our study was to evaluate and compare real-life efficacy and safety of mAbs between young and elder migraine patients.

  • Saved

3yr
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review - European Journal of Medical Research

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review - European Journal of Medical Research

Source : https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00716-w

Background Resistant chronic migraine is a highly disabling condition which is very difficult to treat. The majority of the treatments for migraine prophylaxis are nonspecific and present weak safety profiles,...


Conclusions: Anti-CGRP or anti-CGRP receptor monoclonal antibodies are a promising preventive migraine therapy which can be particularly useful for resistant chronic migraine patients.